<DOC>
	<DOCNO>NCT02769494</DOCNO>
	<brief_summary>This study aim evaluate efficacy safety topical use Mesalazine Sustained-Release Tablets treatment oral ulcer patient Crohn 's disease .</brief_summary>
	<brief_title>The Efficacy Topical Mesalazine Sustained-Release Tablets Crohn 's Disease Patients With Oral Ulcer</brief_title>
	<detailed_description>The study include three phase : screening , treatment follow-up . Screening : This phase last maximum 7 day subject eligibility evaluate informed consent signature . Treatment : Subjects randomly assign treatment treat 7 day . Daily oral ulcer area symptom record treatment period . A randomization visit take place day 0 end-of-treatment visit take place day 6 8 . Follow-up : 28 day end treatment . Efficacy treatment evaluate oral ulcer remission decreasing .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Oral Ulcer</mesh_term>
	<mesh_term>Riboflavin</mesh_term>
	<mesh_term>Flavin Mononucleotide</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Age 18~65 , gender . Patients oral ulcer confirm Crohn 's disease . Contraindications study drug . Underwent accept oral Surgery . Patients able sign inform consent comply study protocol . Planning pregnancy , pregnancy lactate woman . Enrolled clinical trial past 30 day . Patients concurrent / new serious disease affect effectiveness safety evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Oral ulcer</keyword>
	<keyword>Crohn 's disease</keyword>
</DOC>